BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Procognia Limited Wins Health Canada Deal


4/15/2013 9:48:50 AM

Rehovot, Israel, April 14, 2013 -- Health Canada, the department of the government of Canada responsible for national public health, is using Procognia’s glycosylation analysis services and products.

Procognia announced today, that it is providing glycosylation analysis products and services to the Biologics and Genetic Therapies Directorate of Health Canada, for research on biotherapeutic products. Health Canada is the Federal department of the government of Canada responsible for helping Canadians maintain and improve their health.

Dr. Ruth Ben Yakar, Procognia’s CEO said today: “We are very proud of Health Canada’s choice to use our glycosylation analysis products and services for research of various biotherapeutic products. We regard it as a vote of confidence in the capabilities of our technologies and of our services”.

Carbohydrates are known to affect the activity, stability and safety of biological products, including therapeutic protiens, vaccines, and stem cells, making it highly important to characterize them in biopharmaceutical products in general and biosimilars in particular.

“Our products and technologies enable analysis of carbohydrates throughput the process of development and manufacturing of biological products, hence enabling our customers in making informed decisions regarding their products for directing manufacturing conditions towards the desired glycosylation profiles” added Dr. Ben Yakar.

About Procognia:

Procognia (Israel) established in 2000, is a world leader in glycobiology and biopharmaceutical analytics. Procognia offers solutions to major challenges in biopharmaceutical and biosimilar development and manufacturing, including comprehensive analytical services for achievement of optimal glycosylation profiles for improved efficacy, safety and biosimilarity. Procognia owns a large database of glycosylation profiles of biosimilar references. Procognia also collaborates with strategic partners for the development of high-yield biosimilar cell lines for higher productivity and lower manufacturing costs, based on proprietary molecular biology methods.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES